Chimeric Trop2 virus-like particles: A potential immunotherapeutic approach against pancreatic cancer

Journal of Immunotherapy

Volumn 34, Issue 3, 2011, Pages 251-263

  Cubas, Rafael ^a,b   Zhang, Sheng ^b   Li, Min ^b   Chen, Changyi ^b   Yao, Qizhi ^a,b  

^a Department of Molecular Virology and Microbiology ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

immunotherapy; pancreatic cancer; Trop2; virus like particles

Indexed keywords

CANCER VACCINE; CELL SURFACE PROTEIN; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; ONCOLYTIC VIRUS; TRANSFORMING GROWTH FACTOR BETA; TROP2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; IMMUNIZATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; VIRUS LIKE AGENT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNIZATION; IMMUNOTHERAPY, ACTIVE; INTERFERON-GAMMA; INTERLEUKIN-10; MACROPHAGES; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; PROTEINS; RECOMBINANT PROTEINS; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; VACCINES, VIRUS-LIKE PARTICLE;

EID: 79953056191     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318209ee72     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909. (Pubitemid 37328891)
3. Mocellin S, Mandruzzato S, Bronte V, et al. Part I: Vaccines for solid tumours. Lancet Oncol. 2004;5:681-689. (Pubitemid 40267853)
4. Gilboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol. 2001;2:789-792.
5. Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett. 2009;279:1-7.
6. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117:1155-1166. (Pubitemid 46718400)
7. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006;16:53-65. (Pubitemid 43139709)
8. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004; 4:941-952. (Pubitemid 39620069)
9. Cubas R, Zhang S, Kwon S, et al. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother. 2009;32: 118-128.
10. Zhang R, Li M, Chen C, et al. SHIV virus-like particles bind and activate human dendritic cells. Vaccine. 2004;23:139-147. (Pubitemid 39505082)
11. Zhang S, Cubas R, Li M, et al. Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells. Mol Immunol. 2009;46: 1988-2001.
12. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389:521-536. (Pubitemid 351874198)
13. Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines. 2009;8:435-445.
14. Muhlmann G, Spizzo G, Gostner J, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2009; 62:152-158.
15. Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290-1295.
16. Cubas R, Li M, Chen C, et al. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009;1796:309-314.
17. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717-726. (Pubitemid 14184610)
18. Yao Q, Kuhlmann FM, Eller R, et al. Production and characterization of simian-human immunodeficiency viruslike particles. AIDS Res Hum Retroviruses. 2000;16:227-236. (Pubitemid 30111959)
19. Wonderlich J, Shearer G, Livingstone A, et al. Induction and measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol. 2006;Chapter 3:Unit 3. 11.
20. Ko HJ, Kim YJ, Kim YS, et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007;67:7477-7486.
21. Ortmann D, Hausmann J, Beuschlein F, et al. Steroidogenic acute regulatory (StAR)-directed immunotherapy protects against tumor growth of StAR-expressing Sp2-0 cells in a rodent adrenocortical carcinoma model. Endocrinology. 2004;145:1760-1766. (Pubitemid 38402384)
22. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol. 2007;18:537-545.
23. + tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28: e26-e31.
24. Shedlock DJ, Shen H. Requirement for CD4T cell help in generating functional CD8T cell memory. Science. 2003;300: 337-339. (Pubitemid 36433726)
25. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
26. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419-426. (Pubitemid 47509552)
27. Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182:240-249.
28. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000;96: 3838-3846.
29. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-174.
30. Plate JM, Plate AE, Shott S, et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother. 2005;54:915-925. (Pubitemid 40991334)
31. Le HK, Graham L, Cha E, et al. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol. 2009;9: 900-909.
32. Melisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008;7: 829-840. (Pubitemid 351551036)
33. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008;112: 610-618.